Work

A hybrid high activity aware framework integrating graph attention network and transformer for half maximal inhibitory concentration prediction

Year: 2026

Type: article

Abstract: Introduction Tyrosine kinase inhibitors targeting the c-KIT receptor are pivotal in the targeted therapy of malignancies such as gastrointestinal stromal tumors (GIST). The bioactivity of these inhibitors is typically quantified by the half-maximal inhibitory concentration (IC 50 ), making its accurate prediction a critical computational task for accelerating the discovery and optimization of anticancer lead compounds. Methods To address this need, we propose HGATT—a hybrid high activity aware framework integrating Graph Attention Network (GAT) and Transformer—for high-accuracy half maximal inhibitory concentration (IC 50 ) prediction of c-KIT inhibitors. The model was trained on inhibitor data targeting c-KIT and related kinase families sourced from the BindingDB and ChEMBL databases. By extracting atom-level graph features, Morgan fingerprints, and physicochemical descriptors from SMILES strings, HGATT constructs a unified molecular representation that integrates both local structural and global information. Its architecture employs multidimensional graph attention mechanisms and gated residual modules to simultaneously capture atomic-level local structural features and macroscopic molecular properties. Stabilized training strategies, including gradient clipping, were adopted to enhance training efficiency and model robustness. Results On an independent test set, HGATT achieved a mean squared error (MSE) of 0.28 and a coefficient of determination (R²) of 0.57, corresponding to an approximate 44% reduction in MSE compared to the second-best baseline. Discussion Experimental results demonstrate that HGATT outperforms not only individual graph neural network (GNN)- and machine learning-based models but also other related drug-target prediction methods and baseline regression approaches, exhibiting superior predictive accuracy.

Source: Frontiers in Immunology

DOI: 10.3389/fimmu.2026.1929215